Drugs / HRS5091
last change Jun 2022 re-read 2 minutes ago

HRS5091

Developed for
chronic hepatitis B virus infection
Investigated by
Jiangsu HengRui Medicine Co., Ltd.

Trials 2 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05273775 Apr → Jun 2022 chronic hepatitis B virus infection Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04480294 Jul 2020 → Nov 2021 chronic hepatitis B virus infection Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HRS5091 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05273775
1

NCT04480294